NCT01421524 2023-12-12
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
Phase 1 Completed
Celgene
National Institutes of Health Clinical Center (CC)
Providence Health & Services
Celgene
Memorial Sloan Kettering Cancer Center
Seagen Inc.
Washington University School of Medicine
Enzon Pharmaceuticals, Inc.